MabThera Inhibits The Destruction Of Joints In Patients With Early Rheumatoid Arthritis

Roche announced recently that MabThera (rituximab) can significantly inhibit structural damage to joints in patients with early rheumatoid arthritis (RA) who have not been treated with methotrexate (MTX), the current standard of care for RA treatment.

More: continued here

Filed under: Arthritis on January 4th, 2009